This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Takeda, Par, Watson, Amneal accused of keeping out anti-inflammatory drug Colcrys competitors

( August 5, 2021, 22:31 GMT | Official Statement) -- MLex Summary: Takeda Pharmaceuticals, Endo Pharmaceuticals, Amneal Pharmaceuticals, Teva Pharmaceutical, and Par Pharmaceutical have been accused of conspiring to limit competition to Takeda’s branded and ‘authorized generic’ anti-inflammatory drug Colcrys. According to the complaint, rather than compete against one another, the companies conspired not to do so, and to conceal that scheme in part in the form of a distribution joint venture between Takeda and Par. Under the joint venture, Par sold Takeda’s product instead of its own, to maintain Takeda’s monopoly, restrict output of Par’s competing product, allocate 100 percent of the market to Takeda’s product for several years, and share with Takeda in the corresponding monopoly prices, all at the expense of purchasers and patients.See document below. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections